Methods: We performed immunohistochemistry for NGF, p75(NGFR) and

Methods: We performed immunohistochemistry for NGF, p75(NGFR) and PCNA in 45 cases SBE-β-CD manufacturer of HCCs, and examined the relationships between the clinicopathologic

factors and the immunohistochemical results. Results : NGF was detected in 84.4% (38/45) of the tumor cells and in 64.4% (29/45) of the non-tumorous hepatocytes. Furthermore, a NGF expression was present in 28.9% (13/45) of the endothelial cells in the HCCs, but in 80% (36/45) of the endothelial cells in the non-tumor liver tissue. The tumor cells were negative for p75(NGFR) in all the HCCs. Although a p75(NGFR) expression was present in all the nerve fibers in the non-tumor liver tissues, it was markedly reduced (42.2%; 19/45) in the HCCs and a p75(NGFR) expression was observed at the sinusoids or around the large vessels. The HCCs expressing NGF, either in the tumor cells or the endothelial cells, showed a larger size than those HCCs that didn’t express NGF. The NGF positive tumors showed

a tendency toward a higher PCNA-labeling index than did the negative tumors. Conclusions: The changed localization of the NGF expression and the decreased expression of p75(NGFR) are associated with hepatic carcinogenesis. We suggest that a NGF expression may contribute to the click here progression of HCC.”

Pigmented lesions include solar lentigines, seborrheic GSK2879552 inhibitor keratoses, dermatosis papulosa nigra, ephelides, cafe-au-lait macules, nevus spilus, Becker’s nevus, postinflammatory hyperpigmentation, melasma, nevocellular nevi, congenital nevi, junctional and compound melanocytic nevi, nevus of Ota and Ito, Hori’s nevus, and blue nevi. Advances in laser technology have resulted in the ability to treat pigmented lesions with greater safety and efficacy.



review the literature on the use of cutaneous laser treatments for pigmented lesions using Medline.


The literature cited the use of various lasers to treat pigmented lesions, including argon, carbon dioxide, erbium-doped yttrium aluminum garnet, Q-switched, long-pulsed ruby, alexandrite, diode, and fractional lasers. For each lesion, we describe the efficacy of laser treatments, treatment intervals, and settings used for a variety of diagnoses.


The treatment of pigmented lesions continues to evolve as new laser technology emerges and improvements in existing devices are made. The ability to treat pigmented lesions with greater efficacy and safety has resulted from recent advances in laser technology.

The authors have indicated no significant interest with commercial supporters.

Comments are closed.